Asep Medical’s Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis

VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company“) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children. According to Dr. Rob Stenstrom, Asep’s Medical Director, “Abdominal pain is one of the most common complaints we see for children in the emergency room, and so it’s important that we identify the difference between simple appendicitis and perforated appendicitis quickly and accurately.”

Read more at prnewswire.com

Related news for (SEPSF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.